GEN Exclusives

More »

GEN News Highlights

More »
Sep 24, 2007

Array BioPharma Gets $40M Upfront in Cancer and Inflammation Partnership with Celgene

  • Celgene will make a $40 million upfront payment to Array BioPharma as part of a partnership focused on cancer and inflammation. Array stands to earn over $700 million more based on various milestones.

    Array will be responsible for all discovery and clinical development through Phase I or Phase IIa. Celgene has the option to select drugs developed under the collaboration that are directed to two of four mutually selected discovery targets. Celgene will then receive exclusive worldwide rights to those drugs, except for Array’s limited co-promotional rights in the U.S.

    Array also entitled to receive for each drug potential milestone payments of approximately $200 million if certain discovery, development, and regulatory milestones are achieved. An additional $300 million will be paid if certain commercial milestones are reached as well as royalties on net sales. Array will retain all rights to the other programs.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Megamerger Dealzapoppin Poll

What company not in this week’s M&A headlines do you think will be at the center of a megamerger, acquisition, or partial selloff this year?